Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abbott nabs lab info systems maker Starlims

This article was originally published in The Gray Sheet

Executive Summary

Diagnostics firm buys laboratory information management systems maker Starlims Technologies for $123 million in cash under a definitive agreement announced Dec. 14. The purchase, which includes web-based applications to help labs store, retrieve and analyze clinical and administrative data, "will provide Abbott with leading products to build upon existing technologies and expertise in the emerging field of health care informatics," Abbott said. The firm is paying $14 per share for Israel-based Starlims, a 47% premium over its Dec. 14 stock price close of $9.50

You may also be interested in...



COVID-19: ResMed Ramps Up CPAP, BPAP Manufacturing To Address Ventilator Shortage

ResMed plans to double or even triple production of intensive ventilators and sleep apnea machines this year amid rising demand by hospitals to use CPAP and BPAP machines to treat COVID-19 patients during the ventilator shortage. 

Industry, Agencies Are Making COVID-19 Partnerships Easy

Organizations like BARDA, CEPI and others are looking to partner with industry to rapidly test, manufacture, package and deploy vaccines and therapeutics, identifying areas they want to work together during BIO’s recent summit.

COVID-19 Economic Fallout May Delay Cell And Gene Therapy Reimbursement Solutions

The economic stress on payers caused by the pandemic will cause a setback in the development of payment approaches for regenerative therapy, Blue Cross Blue Shield executive warns.

Topics

UsernamePublicRestriction

Register

MT028288

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel